Press coverage about Tonix Pharmaceuticals (NASDAQ:TNXP) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tonix Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.5986328830572 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- Tonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in … – Markets Insider (markets.businessinsider.com)
- Tonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in San Francisco (finance.yahoo.com)
- Stocks Communicate Repulsive Price Growth: Tonix Pharmaceuticals Holding Corp. (TNXP) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Tonix Pharmaceuticals (TNXP) Downgraded by ValuEngine (americanbankingnews.com)
- Tonix Pharmaceuticals Holding Corp. (TNXP) CEO Purchases $19,133.00 in Stock (americanbankingnews.com)
Several equities analysts have commented on TNXP shares. ValuEngine downgraded Tonix Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, October 2nd. Aegis reaffirmed a “buy” rating on shares of Tonix Pharmaceuticals in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $8.33.
In other Tonix Pharmaceuticals news, Director Ernest Mario sold 10,000 shares of the company’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $3.57, for a total value of $35,700.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $35,700. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 48,934 shares of company stock worth $172,496 in the last ninety days. 4.00% of the stock is currently owned by corporate insiders.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company?s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.